New Research Study on Amyotrophic Lateral Sclerosis - Pipeline Review | AB Science SA, Acceleron Pharma, Affichem SA

HTF Market Intelligence released a new research report of 551 pages on title 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018' with detailed analysis, forecast and strategies. The study covers key regions that includes North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC) and important players such as AB Science SA, Acceleron Pharma Inc, Affichem SA, Alexion Pharmaceuticals Inc, Anavex Life Sciences Corp, Apogenix AG, Apotex Inc, Aquestive Therapeutics Inc

Request a sample report @ https://www.htfmarketreport.com/sample-report/1442061-amyotrophic-lateral-sclerosis-pipeline-review-5

Summary
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 6, 25, 16, 2, 89, 26 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 32 and 10 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

AB Science SA, Acceleron Pharma Inc, Affichem SA, Alexion Pharmaceuticals Inc, Anavex Life Sciences Corp, Apogenix AG, Apotex Inc, Aquestive Therapeutics Inc, ArmaGen Inc, Avanir Pharmaceuticals Inc, AveXis Inc, Axovant Sciences Ltd, Bactevo Ltd, Bausch Health Companies Inc, BioElectron Technology Corp, Biogen Inc, Biohaven Pharmaceutical Holding Company Ltd, BioHealthonomics Inc, BrainStorm Cell Therapeutics Inc, Calico LLC, CerSci Therapeutics Inc, Chronos Therapeutics Ltd, Chugai Pharmaceutical Co Ltd, Corcept Therapeutics Inc, Corestem Inc, CSPC NBP Pharmaceutical Co Ltd, Cytokinetics Inc, Denali Therapeutics Inc, Disarm Therapeutics Inc, Eisai Co Ltd, Emerald Health Sciences Inc, FPRT Bio Inc, Gemac SA, Genentech Inc, Genervon Biopharmaceuticals LLC, GeNeuro SA, Gilead Sciences Inc, Glialogix Inc, Grifols SA, Hemostemix Inc, Herantis Pharma Plc, InFlectis BioScience, Ionis Pharmaceuticals Inc, Jeil Pharmaceutical Co Ltd, K-Pax Pharmaceuticals Inc, Kadimastem Ltd, KineMed Inc, Kringle Pharma Inc, Kyorin Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, M3 Biotechnology Inc, Maas Biolab, MallInckrodt Plc, MedDay SA, MeiraGTx Holdings Plc, MimeTech Srl, Miragen Therapeutics Inc, Mitsubishi Tanabe Pharma Corp, NeuCyte Inc, Neuralstem Inc, Neurimmune Holding AG, Neurodyn Life Sciences Inc, Neurofx Inc, NeuroSense Therapeutics Ltd, Neurotune AG, New Biotic Inc, Orion Corp, Orphazyme A/S, Oxford BioMedica Plc, Pfizer Inc, Pharnext SA, Plex Pharmaceuticals Inc, Priavoid GmbH, ProMIS Neurosciences Inc, Prosetta Biosciences Inc, Prothena Corp Plc, QurAlis Corp, Relmada Therapeutics Inc, reMYND NV, Revalesio Corp, Sangamo Therapeutics Inc, Teva Pharmaceutical Industries Ltd, TikoMed AB, Tiziana Life Sciences Plc, Treeway BV, Ultragenyx Pharmaceutical Inc, Verge Genomics Inc, ViroMed Co Ltd, Voyager Therapeutics Inc, WAVE Life Sciences Ltd, Yooyoung Pharm Co Ltd, ZZ Biotech LLC

Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/1442061-amyotrophic-lateral-sclerosis-pipeline-review-5

Table of Contents
Table of Contents 2
Introduction 7
Amyotrophic Lateral Sclerosis - Overview 8
Amyotrophic Lateral Sclerosis - Therapeutics Development 9
Amyotrophic Lateral Sclerosis - Therapeutics Assessment 33
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 49
Amyotrophic Lateral Sclerosis - Drug Profiles 90
Amyotrophic Lateral Sclerosis - Dormant Projects 506
Amyotrophic Lateral Sclerosis - Discontinued Products 516
Amyotrophic Lateral Sclerosis - Product Development Milestones 518
Appendix 529List of Tables
Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number o

....Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1442061-amyotrophic-lateral-sclerosis-pipeline-review-5

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=1442061

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand].

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at
www.linkedin.com/company/13388569/
www.facebook.com/htfmarketintelligence/
twitter.com/htfmarketreport
plus.google.com/u/0/+NidhiBhawsar-SEO_Expert?rel=author

This release was published on openPR.